AU777725B2 - Indole-containing and combretastatin-related anti-mitotic and anti-tubulin polymerization agents - Google Patents

Indole-containing and combretastatin-related anti-mitotic and anti-tubulin polymerization agents Download PDF

Info

Publication number
AU777725B2
AU777725B2 AU74934/00A AU7493400A AU777725B2 AU 777725 B2 AU777725 B2 AU 777725B2 AU 74934/00 A AU74934/00 A AU 74934/00A AU 7493400 A AU7493400 A AU 7493400A AU 777725 B2 AU777725 B2 AU 777725B2
Authority
AU
Australia
Prior art keywords
compound
och
cancer
hydrogen
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU74934/00A
Other languages
English (en)
Other versions
AU7493400A (en
Inventor
Mallinath Hadimani
Kevin G. Pinney
Feng Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baylor University
Original Assignee
Baylor University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baylor University filed Critical Baylor University
Publication of AU7493400A publication Critical patent/AU7493400A/en
Application granted granted Critical
Publication of AU777725B2 publication Critical patent/AU777725B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12—Radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/22—Amides of acids of phosphorus
    • C07F9/24—Esteramides
    • C07F9/2454—Esteramides the amide moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/247—Esteramides the amide moiety containing a substituent or a structure which is considered as characteristic of aromatic amines (N-C aromatic linkage)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/572—Five-membered rings
    • C07F9/5728—Five-membered rings condensed with carbocyclic rings or carbocyclic ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
AU74934/00A 1999-09-17 2000-09-15 Indole-containing and combretastatin-related anti-mitotic and anti-tubulin polymerization agents Ceased AU777725B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15463999P 1999-09-17 1999-09-17
US60/154639 1999-09-17
PCT/US2000/025408 WO2001019794A2 (en) 1999-09-17 2000-09-15 Indole-containing and combretastatin-related anti-mitotic and anti-tubulin polymerization agents

Publications (2)

Publication Number Publication Date
AU7493400A AU7493400A (en) 2001-04-17
AU777725B2 true AU777725B2 (en) 2004-10-28

Family

ID=22552133

Family Applications (1)

Application Number Title Priority Date Filing Date
AU74934/00A Ceased AU777725B2 (en) 1999-09-17 2000-09-15 Indole-containing and combretastatin-related anti-mitotic and anti-tubulin polymerization agents

Country Status (6)

Country Link
US (1) US20070082872A1 (enExample)
EP (1) EP1214298B1 (enExample)
JP (1) JP4187441B2 (enExample)
AU (1) AU777725B2 (enExample)
CA (1) CA2383988A1 (enExample)
WO (1) WO2001019794A2 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004515452A (ja) * 2000-05-09 2004-05-27 アリゾナ ボード オブ リーゼンツ アンチチュウブリンアセンブ称する細胞成長抑制剤
BR0111230A (pt) 2000-05-31 2003-06-10 Astrazeneca Ab Composto, e, uso e processo para a preparação do mesmo
AUPR283801A0 (en) * 2001-02-01 2001-03-01 Australian National University, The Chemical compounds and methods
US7528165B2 (en) 2001-12-13 2009-05-05 National Health Research Institutes Indole compounds
TWI317634B (en) 2001-12-13 2009-12-01 Nat Health Research Institutes Aroyl indoles compounds
US7632955B2 (en) 2001-12-13 2009-12-15 National Health Research Institutes Indole compounds
JP2005532280A (ja) 2002-04-03 2005-10-27 アストラゼネカ アクチボラグ 化合物
DE60336646D1 (de) 2003-08-07 2011-05-19 Nat Health Research Institutes Indol-Verbindungen als Inhibitoren der Tubulin-Polymerisation zur Behandlung von angiogenesisbezogenen Erkrankungen
US7456214B2 (en) * 2004-05-03 2008-11-25 Baylor University Chromene-containing compounds with anti-tubulin and vascular targeting activity
WO2006020573A2 (en) * 2004-08-11 2006-02-23 Barbeau Donald L Noncardiotoxic pharmaceutical compounds
US7456289B2 (en) * 2004-12-31 2008-11-25 National Health Research Institutes Anti-tumor compounds
CA2611712C (en) 2005-06-14 2014-05-13 Baylor University Combretastatin analogs with tubulin binding activity
CA2640678C (en) 2006-02-03 2015-03-31 Bionomics Limited Substituted benzofurans, benzothiophenes, benzoselenophenes and indoles and their use as tubulin polymerisation inhibitors
US20100087446A1 (en) * 2007-04-26 2010-04-08 Chakravarty Prasun K 2-substituted indole derivatives as calcium channel blockers
CN106822083A (zh) 2009-08-27 2017-06-13 生物学特性有限公司 用于治疗增生性疾病的联合疗法
JP2013502440A (ja) 2009-08-27 2013-01-24 バイオノミックス リミテッド 黄斑変性の治療
IT1399130B1 (it) 2010-04-01 2013-04-05 Consiglio Nazionale Ricerche Derivati indolici e loro uso in campo medico.
US9353150B2 (en) 2012-12-04 2016-05-31 Massachusetts Institute Of Technology Substituted pyrazino[1′,2′:1 ,5]pyrrolo[2,3-b]-indole-1,4-diones for cancer treatment
WO2014144715A1 (en) 2013-03-15 2014-09-18 Memorial Sloan-Kettering Cancer Center Hsp90-targeted cardiac imaging and therapy
CN104098499B (zh) * 2013-04-08 2016-05-04 上海医药工业研究院 5-苄氧基-2-(4-苄氧基苯基)-3-甲基-1h-吲哚的制备方法
US9944597B2 (en) 2013-09-16 2018-04-17 The Board Of Regents Of The University Of Texas System Polysubstituted pyrroles having microtubule-disrupting, cytotoxic and antitumor activities and methods of use thereof
CN104262229B (zh) * 2014-08-18 2016-10-05 广东颐正达医药科技有限公司 一种2-苯基取代-3-苯甲酰基取代吲哚的制备方法
US10918627B2 (en) 2016-05-11 2021-02-16 Massachusetts Institute Of Technology Convergent and enantioselective total synthesis of Communesin analogs
US11932650B2 (en) 2017-05-11 2024-03-19 Massachusetts Institute Of Technology Potent agelastatin derivatives as modulators for cancer invasion and metastasis
CN107652194B (zh) * 2017-08-08 2020-02-28 首都医科大学附属北京天坛医院 一类用于治疗神经系统疾病的化合物
US10640508B2 (en) 2017-10-13 2020-05-05 Massachusetts Institute Of Technology Diazene directed modular synthesis of compounds with quaternary carbon centers
WO2020247054A1 (en) 2019-06-05 2020-12-10 Massachusetts Institute Of Technology Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof
WO2022182415A1 (en) 2021-02-24 2022-09-01 Massachusetts Institute Of Technology Himastatin derivatives, and processes of preparation thereof, and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3597300A (en) * 1999-02-18 2000-09-04 Baylor University Compositions and methods for use in targeting vascular destruction

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2963288B2 (ja) * 1992-01-14 1999-10-18 株式会社海洋バイオテクノロジー研究所 水中有害付着生物防除剤
US5596106A (en) * 1994-07-15 1997-01-21 Eli Lilly And Company Cannabinoid receptor antagonists
US5886025A (en) * 1997-03-06 1999-03-23 Baylor University Anti-mitotic agents which inhibit tubulin polymerization
US5948808A (en) * 1997-03-07 1999-09-07 The Texas A&M University System Indole-3-carbinol, diindolylmethane and substituted analogs as antiestrogens
US6150395A (en) * 1997-05-30 2000-11-21 The Regents Of The University Of California Indole-3-carbinol (I3C) derivatives and methods
US6001868A (en) * 1997-05-30 1999-12-14 The Regents Of The University Of California Indole-3-carbinol (I3C) derivatives and methods
WO1999034788A1 (en) * 1998-01-09 1999-07-15 Arizona Board Of Regents, A Body Corporate, Acting On Behalf Of Arizona State University Synthesis of phenstatin and prodrugs thereof
US6410584B1 (en) * 1998-01-14 2002-06-25 Cell Pathways, Inc. Method for inhibiting neoplastic cells with indole derivatives
US6162930A (en) * 1998-03-06 2000-12-19 Baylor University Anti-mitotic agents which inhibit tubulin polymerization
DE19946301A1 (de) * 1998-04-02 2001-04-19 Asta Medica Ag Indolyl-3-glyoxylsäure-Derivate mit therapeutisch wertvollen Eigenschaften
DE19814838C2 (de) * 1998-04-02 2001-01-18 Asta Medica Ag Indolyl-3-glyoxylsäure-Derivate mit Antitumorwirkung
US6110963A (en) * 1998-05-12 2000-08-29 American Home Products Corporation Aryl-oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia
US6166069A (en) * 1998-05-12 2000-12-26 American Home Products Corporation Phenyl oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia
US6358992B1 (en) * 1998-11-25 2002-03-19 Cell Pathways, Inc. Method of inhibiting neoplastic cells with indole derivatives
US6521658B1 (en) * 1999-05-28 2003-02-18 Abbott Laboratories Cell proliferation inhibitors
US6849656B1 (en) * 1999-09-17 2005-02-01 Baylor University Indole-containing and combretastatin-related anti-mitotic and anti-tubulin polymerization agents
US6323228B1 (en) * 2000-09-15 2001-11-27 Abbott Laboratories 3-substituted indole angiogenesis inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3597300A (en) * 1999-02-18 2000-09-04 Baylor University Compositions and methods for use in targeting vascular destruction

Also Published As

Publication number Publication date
US20070082872A1 (en) 2007-04-12
JP4187441B2 (ja) 2008-11-26
AU7493400A (en) 2001-04-17
EP1214298A2 (en) 2002-06-19
EP1214298B1 (en) 2012-05-30
CA2383988A1 (en) 2001-03-22
WO2001019794A2 (en) 2001-03-22
WO2001019794A3 (en) 2001-09-27
JP2003509408A (ja) 2003-03-11

Similar Documents

Publication Publication Date Title
EP1214298B1 (en) Indole-containing and combretastatin-related anti-mitotic and anti-tubulin polymerization agents
EP1263763B1 (en) Tubulin binding ligands
AU2001243527A1 (en) Tubulin binding ligands and corresponding prodrug constructs
Pinney et al. A new anti-tubulin agent containing the benzo [b] thiophene ring system
Pinney et al. Synthesis and biological evaluation of aryl azide derivatives of combretastatin A-4 as molecular probes for tubulin
Romagnoli et al. Design, synthesis and structure–activity relationship of 2-(3′, 4′, 5′-trimethoxybenzoyl)-benzo [b] furan derivatives as a novel class of inhibitors of tubulin polymerization
Ty et al. Synthesis and biological evaluation of enantiomerically pure cyclopropyl analogues of combretastatin A4
Wang et al. Design, synthesis, and structure–activity relationship studies of novel millepachine derivatives as potent antiproliferative agents
CA2963390C (en) Synthesis and anticancer activity of aryl and heteroaryl-quinolin derivatives
US6849656B1 (en) Indole-containing and combretastatin-related anti-mitotic and anti-tubulin polymerization agents
EP1751128B1 (en) Chromene-derivatives with anti-tubulin and vascular targeting activity
PL187490B1 (pl) Zastosowanie pochodnej 1,2-etanodiolu lub jej soli do wytwarzania środka wzmacniającego aktywność czynnika wzrostowego nerwu
Huang et al. Synthesis and biological evaluation of (±)-cryptotanshinone and its simplified analogues as potent CDC25 inhibitors
WO2004099139A1 (en) Indole-containing compounds with anti-tubulin and vascular targeting activity
Zhao et al. Design, synthesis and anti-proliferative effects in tumor cells of new combretastatin A-4 analogs
ES2349746T3 (es) Compuestos derivados del cromeno con actividad de diana anti-tibulina y vascular.
Zhao et al. Design of novel carbamate acetylcholinesterase inhibitors based on the multiple binding sites of acetylcholinesterase
Paegle et al. Selenium analogues of rintodestrant (G1T48) as potent estrogen receptor modulators and downregulators
Nguyen Design and synthesis of combretastatin A-1 analogs, small molecule vascular disrupting agents, and bioreductive triggers as potential therapeutic agents for the treatment of cancer.
Shirali Inhibitors of tubulin assembly: designed ligands featuring benzo [b] thiophene, dihydronaphthalene and aroylchromene molecular core structures
Kodet Studies on heteroaromatic schweinfurthin analogues
Ramirez Synthesis of protected amino thymidines and new thiol derivatives of the vascular targeting agent combretastatin A-4.
Vanderwal Attempted enantioselective total synthesis of podophyllotoxin.
Jelinek Discovery and development of dihydronaphthalene-based vascular disrupting agents and combretastatin-related analogs
AU2003270999A1 (en) Anti-mitotic agents which inhibit tubulin polymerization